SCHEMBL23674641

SCHEMBL23674641

Cc1cccc2ncc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.39
CYP2A6 P11509 1/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
BIRC5 O15392 1/20 0.38
PSMB5 P28074 1/20 0.38
TNF P01375 1/20 0.38
NQO2 P16083 1/20 0.37
PTGES O14684 1/20 0.37
KDR P35968 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK1B Q9Y463 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1147558 0.80 BACE1 (0.41) CYP1A2HTTBIRC5KDRDYRK1A
SCHEMBL30666632 0.80 CYP1A2 (0.53) CYP1A2CYP2A6PDE3BPDE3APSMB5
SCHEMBL2633153 0.80 CYP1A2 (0.53) CYP1A2CYP2A6PDE3BPDE3APSMB5
SCHEMBL18318196 0.77 SMN1; SMN2 (0.44) CYP1A2CYP2A6MAPTHTTSMN1; SMN2
SCHEMBL17309719 0.77 CYP1A2 (0.39) CYP1A2CYP2A6MAPK1ALDH1A1MAPT
SCHEMBL5546091 0.77 PDE3B (0.41) CYP1A2CYP2A6MAPK1ALDH1A1PDE3B
SCHEMBL23246961 0.77 MEN1 (0.40) MAPTSMN1; SMN2BIRC5PTGESKDR
SCHEMBL24151481 0.77 KMT2A (0.47) CYP1A2ALDH1A1MAPTHTTNPSR1
SCHEMBL21064338 0.77 CYP1A2 (0.39) CYP1A2CYP2A6ALDH1A1PDE3BPDE3A
SCHEMBL18378968 0.77 CYP1A2 (0.39) CYP1A2CYP2A6SMN1; SMN2PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 US disclosed
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 US disclosed
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 US disclosed
EP-4093400-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF The Trustees of Princeton University (US) 2022-11-30 EP disclosed
WO-2021151062-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERISTY (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PAH, ALDH2, IDH2 CYP1A2 329/4885CYP2A6 1025/4885MAPK1 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.